A new national survey found that while many Americans use a device to monitor their heart, few share that data with their doctor.

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

Much has changed since the 2013 document came out, with new information on pacing devices, techniques, and more.

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...

Intelliguard & Codonics are offering an integrated system tracking medication from receipt at the hospital to it being properly discarded ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...